Comments
Drug firm Zydus Cadila today said it has received final approval from the United States Food and Drug Administration (USFDA) to market Tamoxifen Citrate Tablets USP in the strengths of 10 mg (base) and 20 mg (base).
It (Tamoxifen Citrate Tablets USP) will be manufactured at the group’s formulations manufacturing facility at SEZ in Ahmedabad, the company said in a BSE filing.
The drug is indicated to treat breast cancer, the company said in the filing.
The group now has more than 165 approvals, it added.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.